DDInter1224 DDInter1840
Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines. Minocycline was granted FDA approval on 30 June 1971.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Minocycline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mestranol
Mestranol {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Minocycline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bismuth subsalicylate
Bismuth subsalicylate {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Minocycline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Torasemide
Torasemide {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Minocycline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bismuth subsalicylate
Bismuth subsalicylate {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Minocycline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Minocycline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Torasemide
Torasemide {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Minocycline {u} may lead to a major life threatening interaction when taken with {v} Methoxyflurane
Methoxyflurane {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Minocycline {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Lomitapide {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Minocycline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Theophylline
Theophylline {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Minocycline {u} (Compound) resembles {v} (Compound) Rolitetracycline
Rolitetracycline {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Mestranol and Mestranol (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate and Bismuth subsalicylate (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Trabectedin (Compound)
Minocycline may cause a minor interaction that can limit clinical effects when taken with Torasemide and Torasemide (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Trabectedin (Compound)
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate and Bismuth subsalicylate (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Trabectedin (Compound)
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)
Minocycline may cause a minor interaction that can limit clinical effects when taken with Torasemide and Torasemide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Trabectedin (Compound)
Minocycline may lead to a major life threatening interaction when taken with Methoxyflurane and Methoxyflurane (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Trabectedin (Compound)
Minocycline may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)
Minocycline (Compound) resembles Rolitetracycline (Compound) and Rolitetracycline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)